Does the media favor SRTA or XGN?

In the previous week, Strata Critical Medical had 7 more articles in the media than Exagen. MarketBeat recorded 9 mentions for Strata Critical Medical and 2 mentions for Exagen. Exagen's average media sentiment score of 0.94 beat Strata Critical Medical's score of 0.67 indicating that Exagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Strata Critical Medical 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Exagen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is XGN or FLGT more profitable?

Fulgent Genetics has a net margin of -26.05% compared to Exagen's net margin of -26.61%. Fulgent Genetics' return on equity of -4.93% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% Fulgent Genetics -26.05% -4.93% -4.50%

Does the media prefer XGN or FLGT?

In the previous week, Fulgent Genetics had 1 more articles in the media than Exagen. MarketBeat recorded 3 mentions for Fulgent Genetics and 2 mentions for Exagen. Fulgent Genetics' average media sentiment score of 1.79 beat Exagen's score of 0.94 indicating that Fulgent Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer XGN or CCRN?

In the previous week, Exagen had 1 more articles in the media than Cross Country Healthcare. MarketBeat recorded 2 mentions for Exagen and 1 mentions for Cross Country Healthcare. Exagen's average media sentiment score of 0.94 beat Cross Country Healthcare's score of 0.00 indicating that Exagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cross Country Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, XGN or SBC?

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 2.42 -$19.95M -$0.81 N/A SBC Medical Group $173.61M 2.16 $50.99M $0.47 7.79

Is XGN or SBC more profitable?

SBC Medical Group has a net margin of 27.99% compared to Exagen's net margin of -26.61%. SBC Medical Group's return on equity of 18.81% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% SBC Medical Group 27.99% 18.81% 13.49%

Does the media refer more to XGN or SBC?

In the previous week, SBC Medical Group had 12 more articles in the media than Exagen. MarketBeat recorded 14 mentions for SBC Medical Group and 2 mentions for Exagen. Exagen's average media sentiment score of 0.94 beat SBC Medical Group's score of 0.08 indicating that Exagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SBC Medical Group 0 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Exagen (XGN) Competitors

$6.66 +0.08 (+1.22%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$6.66 0.00 (-0.08%)

As of 08/14/2026 07:49 PM Eastern

Compare

XGN vs. SRTA, TOI, FLGT, CCRN, and SBC

Should you buy Exagen stock or one of its competitors? Exagen's main competitors and comparable companies include Strata Critical Medical (SRTA), Oncology Institute (TOI), Fulgent Genetics (FLGT), Cross Country Healthcare (CCRN), and SBC Medical Group (SBC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Exagen compare to Strata Critical Medical?

Strata Critical Medical (NASDAQ:SRTA) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Strata Critical Medical has a net margin of 15.71% compared to Exagen's net margin of -26.61%. Strata Critical Medical's return on equity of -2.97% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Strata Critical Medical	15.71%	-2.97%	-2.54%
Exagen	-26.61%	-104.46%	-28.93%

Strata Critical Medical has higher revenue and earnings than Exagen. Strata Critical Medical is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Strata Critical Medical	$197.14M	2.59	$41.35M	-$0.04	N/A
Exagen	$66.57M	2.42	-$19.95M	-$0.81	N/A

Strata Critical Medical has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market. Comparatively, Exagen has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market.

Strata Critical Medical presently has a consensus target price of $8.00, suggesting a potential upside of 35.59%. Exagen has a consensus target price of $9.63, suggesting a potential upside of 44.52%. Given Exagen's stronger consensus rating and higher possible upside, analysts plainly believe Exagen is more favorable than Strata Critical Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Strata Critical Medical	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Strata Critical Medical had 7 more articles in the media than Exagen. MarketBeat recorded 9 mentions for Strata Critical Medical and 2 mentions for Exagen. Exagen's average media sentiment score of 0.94 beat Strata Critical Medical's score of 0.67 indicating that Exagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Strata Critical Medical	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.4% of Strata Critical Medical shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 15.5% of Strata Critical Medical shares are owned by insiders. Comparatively, 10.4% of Exagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Strata Critical Medical beats Exagen on 10 of the 16 factors compared between the two stocks.

How does Exagen compare to Oncology Institute?

Oncology Institute (NASDAQ:TOI) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

In the previous week, Exagen had 1 more articles in the media than Oncology Institute. MarketBeat recorded 2 mentions for Exagen and 1 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 1.87 beat Exagen's score of 0.94 indicating that Oncology Institute is being referred to more favorably in the media.

Company	Overall Sentiment
Oncology Institute	Very Positive
Exagen	Positive

Oncology Institute has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Exagen has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market.

36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 4.4% of Oncology Institute shares are owned by company insiders. Comparatively, 10.4% of Exagen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Exagen has lower revenue, but higher earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$545.76M	0.94	-$60.61M	-$0.37	N/A
Exagen	$66.57M	2.42	-$19.95M	-$0.81	N/A

Oncology Institute has a net margin of -7.42% compared to Exagen's net margin of -26.61%. Oncology Institute's return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-7.42%	N/A	-24.68%
Exagen	-26.61%	-104.46%	-28.93%

Oncology Institute currently has a consensus price target of $8.50, indicating a potential upside of 63.90%. Exagen has a consensus price target of $9.63, indicating a potential upside of 44.52%. Given Oncology Institute's higher probable upside, equities analysts plainly believe Oncology Institute is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Exagen beats Oncology Institute on 10 of the 17 factors compared between the two stocks.

How does Exagen compare to Fulgent Genetics?

Exagen (NASDAQ:XGN) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

75.3% of Exagen shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 10.4% of Exagen shares are owned by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Fulgent Genetics had 1 more articles in the media than Exagen. MarketBeat recorded 3 mentions for Fulgent Genetics and 2 mentions for Exagen. Fulgent Genetics' average media sentiment score of 1.79 beat Exagen's score of 0.94 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Exagen presently has a consensus target price of $9.63, suggesting a potential upside of 44.52%. Fulgent Genetics has a consensus target price of $27.50, suggesting a potential upside of 48.17%. Given Fulgent Genetics' higher possible upside, analysts clearly believe Fulgent Genetics is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Exagen has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Exagen has higher earnings, but lower revenue than Fulgent Genetics. Exagen is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	2.42	-$19.95M	-$0.81	N/A
Fulgent Genetics	$323.93M	1.58	-$60.51M	-$2.82	N/A

Fulgent Genetics has a net margin of -26.05% compared to Exagen's net margin of -26.61%. Fulgent Genetics' return on equity of -4.93% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

Summary

Fulgent Genetics beats Exagen on 9 of the 17 factors compared between the two stocks.

How does Exagen compare to Cross Country Healthcare?

Exagen (NASDAQ:XGN) and Cross Country Healthcare (NASDAQ:CCRN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

Cross Country Healthcare has a net margin of -9.84% compared to Exagen's net margin of -26.61%. Cross Country Healthcare's return on equity of -0.74% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
Cross Country Healthcare	-9.84%	-0.74%	-0.54%

Exagen presently has a consensus price target of $9.63, suggesting a potential upside of 44.52%. Cross Country Healthcare has a consensus price target of $12.05, suggesting a potential downside of 9.06%. Given Exagen's stronger consensus rating and higher probable upside, equities analysts clearly believe Exagen is more favorable than Cross Country Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Cross Country Healthcare	1 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.90

Exagen has higher earnings, but lower revenue than Cross Country Healthcare. Exagen is trading at a lower price-to-earnings ratio than Cross Country Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	2.42	-$19.95M	-$0.81	N/A
Cross Country Healthcare	$1.00B	0.43	-$94.85M	-$3.05	N/A

In the previous week, Exagen had 1 more articles in the media than Cross Country Healthcare. MarketBeat recorded 2 mentions for Exagen and 1 mentions for Cross Country Healthcare. Exagen's average media sentiment score of 0.94 beat Cross Country Healthcare's score of 0.00 indicating that Exagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cross Country Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

75.3% of Exagen shares are held by institutional investors. Comparatively, 96.0% of Cross Country Healthcare shares are held by institutional investors. 10.4% of Exagen shares are held by insiders. Comparatively, 6.3% of Cross Country Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Exagen has a beta of 2.05, indicating that its stock price is 105% more volatile than the broader market. Comparatively, Cross Country Healthcare has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market.

Summary

Exagen beats Cross Country Healthcare on 11 of the 17 factors compared between the two stocks.

How does Exagen compare to SBC Medical Group?

Exagen (NASDAQ:XGN) and SBC Medical Group (NASDAQ:SBC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

75.3% of Exagen shares are owned by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are owned by institutional investors. 10.4% of Exagen shares are owned by insiders. Comparatively, 81.7% of SBC Medical Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

SBC Medical Group has a net margin of 27.99% compared to Exagen's net margin of -26.61%. SBC Medical Group's return on equity of 18.81% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
SBC Medical Group	27.99%	18.81%	13.49%

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	2.42	-$19.95M	-$0.81	N/A
SBC Medical Group	$173.61M	2.16	$50.99M	$0.47	7.79

In the previous week, SBC Medical Group had 12 more articles in the media than Exagen. MarketBeat recorded 14 mentions for SBC Medical Group and 2 mentions for Exagen. Exagen's average media sentiment score of 0.94 beat SBC Medical Group's score of 0.08 indicating that Exagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SBC Medical Group	0 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Exagen has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

Exagen currently has a consensus target price of $9.63, indicating a potential upside of 44.52%. SBC Medical Group has a consensus target price of $8.50, indicating a potential upside of 132.24%. Given SBC Medical Group's higher possible upside, analysts plainly believe SBC Medical Group is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
SBC Medical Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

SBC Medical Group beats Exagen on 10 of the 17 factors compared between the two stocks.

Get Exagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XGN vs. The Competition

Export

Metric	Exagen	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$161.34M	$9.87B	$7.03B	$13.07B
Dividend Yield	N/A	2.54%	2.57%	10.64%
P/E Ratio	-8.22	35.17	271.54	25.40
Price / Sales	2.42	4.87	673.88	125.76
Price / Cash	N/A	124.24	75.70	53.27
Price / Book	13.32	3.94	12.92	6.21
Net Income	-$19.95M	$309.96M	$3.45B	$347.71M
7 Day Performance	-3.06%	0.09%	1.17%	1.08%
1 Month Performance	56.71%	-0.34%	2.18%	1.87%
1 Year Performance	-29.82%	19.48%	62.39%	20.79%

Exagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XGN Exagen	3.9622 of 5 stars	$6.66 +1.2%	$9.63 +44.5%	-29.8%	$161.34M	$66.57M	N/A	220
SRTA Strata Critical Medical	2.375 of 5 stars	$5.93 -0.8%	$8.00 +35.0%	N/A	$512.69M	$197.14M	N/A	130	News Coverage
TOI Oncology Institute	3.3629 of 5 stars	$5.19 +1.1%	$8.50 +63.9%	+37.9%	$512.58M	$545.76M	N/A	660	Positive News Gap Down
FLGT Fulgent Genetics	3.5706 of 5 stars	$18.58 -0.4%	$27.50 +48.0%	-12.7%	$511.14M	$322.67M	N/A	1,315	Positive News
CCRN Cross Country Healthcare	1.6048 of 5 stars	$13.25 flat	$12.05 -9.1%	N/A	$428.05M	$1.00B	N/A	6,784

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XGN) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exagen (XGN) Competitors

XGN vs. SRTA, TOI, FLGT, CCRN, and SBC

How does Exagen compare to Strata Critical Medical?

Summary

How does Exagen compare to Oncology Institute?

Summary

How does Exagen compare to Fulgent Genetics?

Summary

How does Exagen compare to Cross Country Healthcare?

Summary

How does Exagen compare to SBC Medical Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exagen (XGN) Competitors

XGN vs. SRTA, TOI, FLGT, CCRN, and SBC

How does Exagen compare to Strata Critical Medical?

Is SRTA or XGN more profitable?

Which has stronger earnings & valuation, SRTA or XGN?

Which has more volatility and risk, SRTA or XGN?

Do analysts rate SRTA or XGN?

Does the media favor SRTA or XGN?

Do institutionals & insiders have more ownership in SRTA or XGN?

Summary

How does Exagen compare to Oncology Institute?

Does the media favor TOI or XGN?

Which has more volatility and risk, TOI or XGN?

Do institutionals and insiders have more ownership in TOI or XGN?

Which has stronger valuation and earnings, TOI or XGN?

Is TOI or XGN more profitable?

Do analysts prefer TOI or XGN?

Summary

How does Exagen compare to Fulgent Genetics?

Do insiders and institutionals hold more shares of XGN or FLGT?

Does the media prefer XGN or FLGT?

Do analysts recommend XGN or FLGT?

Which has more risk and volatility, XGN or FLGT?

Which has stronger valuation and earnings, XGN or FLGT?

Is XGN or FLGT more profitable?

Summary

How does Exagen compare to Cross Country Healthcare?

Is XGN or CCRN more profitable?

Do analysts prefer XGN or CCRN?

Which has stronger earnings and valuation, XGN or CCRN?

Does the media prefer XGN or CCRN?

Do insiders & institutionals have more ownership in XGN or CCRN?

Which has more volatility & risk, XGN or CCRN?

Summary

How does Exagen compare to SBC Medical Group?

Do institutionals and insiders believe in XGN or SBC?

Is XGN or SBC more profitable?

Which has stronger earnings and valuation, XGN or SBC?

Does the media refer more to XGN or SBC?

Which has more risk & volatility, XGN or SBC?

Do analysts recommend XGN or SBC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools